Welcome to BioSeeker Group!

Triple Analysis: Leukemia, Lymphoma and Protein Kinase Inhibitors

Additional Information

Published Date May 1, 2012
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 5041
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Leukemia, Lymphoma and Protein Kinase Inhibitors in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in both Leukemia and Lymphoma and by the mechanism/target/effect of Protein Kinase Inhibitors.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Leukemia, Lymphoma and Protein Kinase Inhibitors.

    To find out more about Triple Analysis: Leukemia, Lymphoma and Protein Kinase Inhibitors, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Leukemia, Lymphoma and Protein Kinase Inhibitors is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in both Leukemia and Lymphoma and by the mechanism/target/effect of Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Leukemia
The leukemia report part comprises defined and up to date development strategies for 313 leukemia drugs within the portfolio of 186 investigators, from Ceased to Marketed. This part extensively analyses their 204 identified drug targets, organized into 193 drug target strategies, and assesses them in eight different compound strategies and and eight subindications of leukemia.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market

Part II: Lymphoma
The lymphoma report part comprises defined and up to date development strategies for 282 lymphoma drugs within the portfolio of 154 investigators, from Ceased to Marketed. This part extensively analyses their 181 identified drug targets, organized into 173 drug target strategies, and assesses them in eight different compound strategies and and five subindications of lymphoma.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market

Part III: Protein Kinase Inhibitors
The protein kinase drug report part comprises defined and up to date development strategies for 648 drugs in oncology within the portfolio of 212 companies world-wide, from Ceased to Marketed. The report extensively analyses their 183 identified drug targets, organized into 278 drug target strategies, and assesses them in 70 cancer indications.
This part is based on the following publication:
Competitive Insights to Protein Kinase Therapeutics in Oncology: The Faster Route to Consider Your Options and Position of Others

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Leukemia
5.1 The Scope of this Report 29
6 Consider the Therapeutic Target Among Leukemia Drugs for the Highest Therapeutic Outcome and Return on Investment (204 Drug Targets) 33-443
7 Emerging New Products to Established Ones: Drug Target Strategies of Leukemia Drugs by their Highest Stage of Development (193 Drug Target Strategies and 313 Leukemia Drugs) 444-727
8 Compound Strategies at Work: Competitive Benchmarking of Leukemia Drugs by Compound Strategy (8 Compound Strategies) 679-728
9 Selecting Subindication for Leukemia Drugs (8 Subindications of Leukemia) 729-762
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Leukemia Drug Pipeline by Investigator (186 Companies) 763-1,129
11 Disclaimer 1130
12 Drug Index 1131
13 Company Index 1140
Figures: Includes 6 Figures
Tables: Includes 253 Tables
Total Number of Pages: 1,147

Part II: Lymphoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Lymphoma Drugs for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 30-387
7 Emerging New Products to Established Ones: Drug Target Strategies of Lymphoma Drugs by their Highest Stage of Development (173 Drug Target Strategies and 282 Lymphoma Drugs) 388-596
8 Compound Strategies at Work: Competitive Benchmarking of Lymphoma Drugs by Compound Strategy (8 Compound Strategies) 597-636
9 Selecting Subindication for Lymphoma Drugs (Five Subindications of Lymphoma) 637-657
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lymphoma Drug Pipeline by Investigator (152 Companies) 658-938
11 Disclaimer 939
12 Drug Index 940
13 Company Index 948
Figures: Includes 6 Figures
Tables: Includes 222 Tables
Total Number of Pages: 954

Part III: Protein Kinase Inhibitors
5.1 The Scope of this Report 38
6 Consider the Therapeutic Target Among Protein Kinase Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (183 Drug Targets) 42-516
7 Emerging New Products to Established Ones: Drug Target Strategies of Protein Kinase Drugs in Oncology by their Highest Stage of Development (278 Drug Target Strategies and 648 Drugs) 517-945
8 Compound Strategies at Work: Competitive Benchmarking of Protein Kinase Cancer Drugs by Compound Strategy (8 Compound Strategies) 946-1013
9 Selecting Indication for Protein Kinase Drugs in Oncology (70 Cancer Indications) 1014-1223
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Protein Kinase Drug Pipeline in Oncology by Investigator (212 Investigators and 648 Drugs) 1224-2939
11 Disclaimer 2940
Figures: Includes 8 Figures
Tables: Includes 389 Tables
Total Number of Pages: 2,940

This Report Includes the Following Companies:
3M Pharmaceuticals
4SC
AB Science
Abbott
Abiogen
Acceleron Pharma
ACT Biotech
Actinium Pharmaceuticals
Advaxis
Advenchen
AEgera
AEterna Zentaris
Affimed Therapeutics
Agenus
Aida Pharmaceuticals
Alethia Biotherapeutics
Alexion
Alfa Wassermann
Alfacell
Allist Pharmaceuticals
Allos Therapeutics
Allostera
AlphaVax
Altor BioScience
Ambit Biosciences
Amgen
Amphora
Ansaris
Antisoma
Apogee Biotechnology
Apricus Biosciences
Arca biopharma
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Asahi Kasei Pharma
Ascenta Therapeutics
Astellas
Astex Pharmaceuticals
Astex Therapeutics
AstraZeneca
Attenuon
AVEO
Avila Therapeutics
Bavarian Nordic
Bayer
Benitec
Berkeley Lab
Bio-Path Holdings
BioAxone
Biocon
BioCryst Pharmaceuticals
Bioenvision
Biogen Idec
Biolex
Bionovo
BioSante
Biotecnol
Biotica Technology
Bioton
Boehringer Ingelheim
Borean Pharma
Bristol-Myers Squibb
BTG
Callisto Pharmaceuticals
Cambrex
CanBas
Cancer Research Technology
Catalyst Biosciences
Celator Pharmaceuticals
Celera
Celgene
Cell Therapeutics
CellCeutix
Celldex Therapeutics
Celleron
Celltrion
Cephalon
CerRx
Choongwae
Chroma Therapeutics
Circadian Technologies
CJ Corp
Clavis Pharma
Cleveland BioLabs
Clinical Data
CompleGen
Compugen
CoNCERT Pharmaceuticals
Cornerstone Pharmaceuticals
CSL
Curacyte
CureTech
Curis
Cyclacel
Cylene Pharmaceuticals
CytImmune Sciences
Cytokine PharmaSciences
Cytokinetics
Cytopia
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Debiopharm
Deciphera Pharmaceuticals
Dendreon
DeveloGen
DiaMedica
Dong-A
Dr Reddy’s
Dyax
Dynavax Technologies
Eisai
Elara Pharmaceuticals
Eleos
Eli Lilly
Emergent BioSolutions
Enkam Pharmaceuticals
EntreMed
Enzon
EpiCept
Epizyme
Erimos
Esperance Pharmaceuticals
Exelixis
ExonHit Therapeutics
Favrille
Forma Therapeutics
Galapagos
Galena Biopharma
Gemin X Biotechnologies
Genencor
Genentech
Generex
Genmab
GenPat77
Genta
Genzyme
Geron
Gilead Sciences
GlaxoSmithKline
GlycoGenesys
GlycoMimetics
GPC Biotech
Hanmi
Hayashibara
Heber Biotec
HemaQuest
Hoffmann-La Roche
Human Genome Sciences
Hutchison China MediTech
Hy BioPharma
Hypha Discovery
Idera Pharmaceuticals
IDM Pharma
IGF Oncology
IkerChem
ImClone Systems
Immune Pharmaceuticals
Immunocore
ImmunoFrontier
ImmunoGen
Immunomedics
Incozen Therapeutics
Incyte Corporation
InDex Pharmaceuticals
Inex
Inhibiton Therapeutics
Innate Pharma
InNexus Biotechnology
Innovive
Inovio
Insmed
Insys Therapeutics
Intas Biopharmaceuticals
Intellikine
Intracel
Isis Pharmaceuticals
ISU ABXIS
Italfarmaco
Jina Pharmaceuticals
Johnson & Johnson
Kadmon
KAI Pharmaceuticals
KaloBios
Kalypsys
Kanisa
Karus Therapeutics
Keryx Biopharmaceuticals
Kiadis
Kinex
Kirin Pharma
Kissei
KuDOS
Kyowa Hakko Kirin
Leo
Lexicon Pharmaceuticals
LFB Biotechnologies
LG Life Sciences
Ligand
Lorus Therapeutics
MacroGenics
Marina Biotech
MAT Biopharma
MaxCyte
MaxoCore Pharmaceuticals
Meda
MediGene
MedImmune
Medisyn Technologies
Memgen
Merck & Co
Merck KGaA
Merrimack
MethylGene
Micromet
Mitsubishi Tanabe Pharma
Molecular LogiX
Mologen
Myrexis
Nano Terra
Nektar Therapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
NexusPharma
NicOx
Nidus Laboratories
NIH
Nippon Shinyaku
Non-industrial source
NovaLead
Novartis
Novogen
Noxxon
Nycomed Pharma
Oncalis
Onconova
OncoTherapy Science
Oncothyreon
OSI Pharmaceuticals
Otsuka
Pathway Therapeutics
Peregrine Pharmaceuticals
Pfizer
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
Philogen
Phoenix Biotechnology
PHusis Therapeutics
Pieris
PIERIS Proteolab
Pierre Fabre
Piramal
PIramed
Plexxikon
Portola Pharmaceuticals
Proacta
Prochon Biotech
Progenics Pharmaceuticals
ProMetic Life Sciences
ProNAi Therapeutics
Provid
QLT
Quantum Pharmaceuticals
Ras Therapeutics
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Reliance Life Sciences
Rexahn
Rigel
Samtheo Biopharma
Sangamo BioSciences
Sanofi
Sanofi-Aventis
Santaris Pharma
Sareum
SBI Biotech
SBIO
Scancell
Schering-Plough
Seattle Genetics
Selvita
Semafore Pharmaceuticals
Sentinel Oncology
Sepal Pharma
Servier
SGX Pharmaceuticals
Shenogen
Shire
Sidus
Silence Therapeutics
Southern Research Institute
Spirogen
Stemline Therapeutics
Sunesis
SuperGen
SuppreMol
Supratek Pharma
Swedish Orphan Biovitrum
Switch Pharma
SymBio Pharmaceuticals
Symbiotec
Symphogen
Synageva BioPharma
Synta Pharmaceuticals
Syntrix
Takeda
Talon Therapeutics
Tamir Biotechnology
Tapestry Pharmaceuticals
Targa Therapeutics
TargeGen
TauTaTis
TCD Pharma
TeGenero
Tekmira Pharmaceuticals
Telik
TetraLogic Pharmaceuticals
Teva
Thallion Pharmaceuticals
Theryte
Tigris Pharmaceuticals
Titan Pharmaceuticals
ToolGen
TopoTarget
Tragara Pharmaceuticals
Transgene
TransTech Pharma
Trion Pharma
UCB
Vaccinex
Valeant
VasGene Therapeutics
Velacor Therapeutics
VentiRx Pharmaceuticals
Vernalis
Vertex Pharmaceuticals
Vion Pharmaceuticals
VioQuest
VioQuest Pharmaceuticals
ViroMed
Wyeth
XBiotech
Xcovery
Xencor
Yakult Honsha
Yamasa Corporation
YM BioSciences
Zenotech
Zenyaku Kogyo
A Shortlist of Drugs Included are:
131I-tositumomab
AC-480
AE-37
AF-802
afatinib
alemtuzumab
alvocidib
AMG-386
amonafide malate
amrubicin hydrochloride
amsacrine
Angiozyme
apatinib
AR-42
ARQ-197
AT-7519
AT-9283
axitinib
AZD-8055
AZD-8931
bafetinib
barasertib
bardoxolone methyl
belinostat
bexarotene
BEZ-235
BGT-226
BI-811283
BIBF-1120
bisantrene
BMS-690514
BMS-754807
BMS-777607
bortezomib
bosutinib
brentuximab vedotin
brivanib alaninate
Cabozantinib
CAL-101
CBP-501
CC-223
cediranib
cladribine
clofarabine
crizotinib
CSF-GM
cytarabine ocfosfate
cytarabine, injectable
dacomitinib
danusertib
dasatinib
daunorubicin
decitabine
denileukin diftitox
dinaciclib
dovitinib lactate
E-75
elacytarabine
elliptinium acetate
endoxifen
ENMD-2076
enocitabine
enzastaurin hydrochloride
epirubicin
erlotinib
everolimus
foretinib
fostamatinib disodium
galiximab
gefitinib
gemtuzumab ozogamicin
GSK-2118436
HBP-347
histamine dihydrochloride
ibritumomab tiuxetan
IC-83
icrucumab
idarubicin
idronoxil
imatinib mesilate
INCB-028060
inotuzumab ozogamicin
INSM-18
interferon
interferon (alpha-N1)
interferon (alpha)
interferon (alpha2)
interferon (alpha2a)
interferon (alpha2b)
interferon (alpha2c)
interferon (gamma)
interferon alfa-2b
interferon alpha-2b
irinotecan hydrochloride
JI-101
KD032
KX2-391
lapatinib ditosylate
lenvatinib
lestaurtinib
leukemia vaccine
linifanib
linsitinib
lumiliximab
LY-2090314
masitinib
MGCD-265
midostaurin
mitoxantrone
MK-1775
MKC-1
MLN-8237
MM-111
motesanib diphosphate
MVA-BN Her-2 vaccine
neratinib
nilotinib
NPB-001-056
obinutuzumab
oblimersen sodium
ofatumumab
ON-01910
onartuzumab
OSI-027
OTS-102
P276-00
panobinostat
pazopanib hydrochloride
PD-0332991
pegdinetanib
peginterferon alfa-2b
pentostatin
perifosine
PHA-848125AC
pixantrone
plitidepsin
ponatinib
pralatrexate
PX-866
quinacrine
quizartinib dihydrochloride
RAF-265
ramucirumab
razoxane
Reditux
regorafenib
rhIFN-alpha
ridaforolimus
rilotumumab
rituximab
romidepsin
ruxolitinib
RX-0201-N
SCH-900776
seliciclib
sirolimus
sobuzoxane
sorafenib tosylate
ß-lapachone
SU-6668
sunitinib malate
talmapimod
tamibarotene
tandutinib
telatinib
temsirolimus
teniposide
terameprocol
tipifarnib
tivozanib
triciribine phosphate
vandetanib
varlitinib
vemurafenib
volasertib
vosaroxin
XL-147
XL-281
XL-413
XL-647
XL-765
zanolimumab
zorubicin

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Leukemia, Lymphoma and Protein Kinase Inhibitors.
    To find out more about Triple Analysis: Leukemia, Lymphoma and Protein Kinase Inhibitors, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Leukemia, Lymphoma and Protein Kinase Inhibitors is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Apoptosis, Angiogenesis and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies by mechanism/target/effect of Apoptosis, Angiogenesis and Protein Kinase Inhibitors. Learn More


Triple Analysis: Lymphoma, Melanoma and Angiogenesis
This triple analysis focuses on cancer drug development strategies in both Lymphoma and Melanoma and by the mechanism/target/effect of Angiogenesis. Learn More

Other selected research from the 'Oncology' category:


Biologicals in Oncology: Drug Pathway Analyzer
There are today at least 2306 biological drugs known to affect more than 269 specific intracellular signaling pathways for the treatment of more than 175 different tumor types. The rational for this plethora of treatment strategies is based on our increasing understanding of the 674 drug targets that are included in this drug-pathway analyzing tool. No less than 607 of these have been recorded with mutations and 76 drug targets have mutations which have been causally implicated in cancer. Learn More


Triple Analysis: Colorectal Cancer, Apoptosis and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in Colorectal Cancer and by the two mechanism/target/effect areas of Apoptosis and Protein Kinase Inhibitors. Learn More